Sarcomas

Jonathan C. Trent, MD, PhD, sheds light on the impact of COVID-19 on the treatment of rare cancers.

Jonathan C. Trent, MD, PhD, discusses research efforts in bone and soft tissue sarcomas.

Hui-Zi Chen, MD, PhD, discusses the use of rapid research autopsy in metastatic ultra-hypermutated interdigitating dendritic cell sarcoma, an extremely rare cancer of dendritic origin that lacks a standardized treatment approach.

John A. Abraham, MD, FACS, discusses potential symptoms of tenosynovial giant cell tumor.

Gina Z. D'Amato, MD, discusses the evolution of treatment in sarcoma, the use of next-generation sequencing, and predictive and prognostic biomarkers under investigation in the space.

R. Lor Randall, MD, FACS, discusses current approaches in the surgical management of patients with osteosarcoma that has metastasized to the lungs.

Avapritinib did not improve progression-free survival versus regorafenib in previously treated patients with locally advanced unresectable or metastatic gastrointestinal stromal tumor, missing the primary end point of the phase 3 VOYAGER trial.

John A. Abraham, MD, FACS, discusses the role of surgery in the treatment of tenosynovial giant cell tumor, key challenges faced in this space, and the emergence of pexidartinib.

The China National Medical Products Administration has accepted a new drug application for avapritinib for 2 indications in gastrointestinal stromal tumors.

Brian Van Tine, MD, PhD, discusses what tazemetostat’s approval brings to the treatment landscape for patients with epithelioid sarcoma.

Gina Z. D'Amato, MD, discusses the emerging role of next-generation sequencing in sarcoma.